No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: No P/S history yet
Annual revenue · last 2 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:00:55.549Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Aktis Oncology, Inc. (AKTS) stock was $18.52 as of Oct 5, 2026, 4:00 PM EDT, unchanged from the previous close.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment.
Biotechnology · Boston, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.47
Revenue Est.
$3.83M
Last Quarter Results
EPS
$-0.44
vs Estimate
$-0.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AKTS | $989.05M | $18.52 | +0.00% | N/A | N/A | N/A | N/A |
| 2CGEM | $985.79M | $16.04 | +3.42% | +170.57% | -7.48% | N/A | vs AKTS |
| 3CBLL | $943.26M | $24.86 | +4.94% | +96.04% | N/A | N/A | vs AKTS |
| 4TDOC | $1.05B | $5.79 | +4.89% | -35.60% | -45.85% | -10.53% | vs AKTS |
| 5ABUS | $922.50M | $4.67 | +4.94% | +6.59% | +2.19% | +2.93% | vs AKTS |
| 6BVS | $915.95M | $13.52 | +2.97% | +91.99% | -0.81% | N/A | vs AKTS |
forward FY estimate
N/A
$3.38M
vs Estimate
$2.63M
Consensus Rating
Based on 9 analysts
Average Price Target
$35.39
+91.1% upside
Low
$31.50
Current
$18.52
High
$40.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.55 | $-0.46 | $-0.34 | 7 |
| Quarter ending Dec 2026 | $-0.54 | $-0.50 | $-0.45 | 6 |
| Quarter ending Mar 2027 | $-0.67 | $-0.59 | $-0.46 | 2 |
| Quarter ending Jun 2027 | $-0.70 | $-0.61 | $-0.47 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.91 | $-1.79 | $-1.46 | 7 |
| FY 2027 | $-3.01 | $-2.26 | $-1.49 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $3.18M | $3.83M | $4.26M | 6 |
| Quarter ending Dec 2026 | $4.73M | $5.71M | $6.34M | 6 |
| Quarter ending Mar 2027 | $1.17M | $1.41M | $1.57M | 3 |
| Quarter ending Jun 2027 | $1.16M | $1.39M | $1.55M | 3 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $9.60M | $15.01M | $17.38M | 7 |
| FY 2027 | $4.98M | $13.00M | $29.02M | 7 |
